N-[4,5-Dihydroxy-6-hydroxymethyl-2-(naphthalen-2-yloxy)-tetrahydro-pyran-3-yl]-acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[4,5-Dihydroxy-6-hydroxymethyl-2-(naphthalen-2-yloxy)-tetrahydro-pyran-3-yl]-acetamide
• 英文别名: N-[4,5-dihydroxy-6-(hydroxymethyl)-2-naphthalen-2-yloxyoxan-3-yl]acetamide
• 化学式: C₁₈H₂₁NO₆
• 分子量: 347.4
• InChiKey: QKMSGRRTZKSWCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• EPITOPE REDUCTION THERAPY
  申请人：Crispin Matthew David Max

  公开号：US20100022620A1

  公开（公告）日：2010-01-28

  The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.
• SUBSTRATE REDUCTION THERAPY
  申请人：Platt Mary Frances

  公开号：US20100204162A1

  公开（公告）日：2010-08-12

  The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
• TREATMENT OF MYCOBACTERIAL INFECTION
  申请人：Oxford University Innovation Limited

  公开号：US20180125796A1

  公开（公告）日：2018-05-10

  The invention provides a combination comprising a SERCA antagonist and an inhibitor of glycosphingolipid biosynthesis, for use in the treatment of an infection by a pathogenic mycobacterium . The combination may for instance be used to treat tuberculosis.
• US8557844B2
  申请人：——

  公开号：US8557844B2

  公开（公告）日：2013-10-15
• US9428541B2
  申请人：——

  公开号：US9428541B2

  公开（公告）日：2016-08-30